Finerenone significantly decreased the primary outcome, which was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure by 13% and showed a trend toward less CKD progression relative to placebo after a mean follow‐up of 3.4 years. 17 We recently reported the beneficial effect of MR blockade by finerenone in the Zucker fatty/spontaneously hypertensive rat, a model associating hypertension and features of HFpEF such as diastolic dysfunction, cardiac fibrosis, and reduced exercise capacity in a context of obesity and type 2 diabetes.
← all excerpts
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.
1
—
—